Shanghai Henlius Biotech (2696) investor relations material

Executive summary

• 2026 H1 revenue reached RMB 3.59B, up 27.3% year-over-year, driven by drug sales, R&D services, and licensing income.

• Net profit for 2026 H1 was RMB 430.4M, a 10.3% increase year-over-year, with Non-IFRS profit at RMB 572.3M and EBITDA at RMB 904.1M.

• Over 1,100,000 patients benefited globally; 10 products (41 indications) approved in over 60 countries/regions.

• Significant product launches and regulatory milestones achieved in China, the US, EU, Korea, and other regions.

Financial highlights

• Gross profit for 2026 H1 was RMB 2.77B, up 25.9% year-over-year.

• Ex-China/overseas product revenue surged 159.4% year-over-year to RMB 110M, with overseas profit exceeding fourfold growth.

• R&D expenditure increased 45.8% year-over-year to RMB 1.45B, supporting innovation and pipeline expansion.

• Cash and bank balances stood at RMB 818M as of June 30, 2026.

• BD and other revenue grew 167.3% year-over-year to RMB 702M.

Outlook and guidance

• More than 10 new products expected to launch globally in the next few years, driven by a robust biosimilar and innovative pipeline.

• Plans to submit BLAs for HANSIZHUANG (ES-SCLC) and HANBEITAI in the US and EU in 2026.

• Continued focus on international expansion, leveraging AI in R&D, and strategic partnerships to maximize commercial synergies.

• Key clinical milestones anticipated in H2 2026 and 2027, including pivotal data readouts and regulatory submissions.